Cost-effectiveness analysis of a universal rotavirus immunization program in Japan

Abstract

In anticipation of the imminent licensure of rotavirus vaccine, we evaluated the costeffectiveness of rotavirus vaccine in Japan by taking into account the considerable variations in the incidence of rotavirus-associated hospitalizations previously reported in the literature.We assumed that the variation was due to local differences in healthcare utilization practices rather than a true difference in the incidence of severe rotavirus gastroenteritis. Thus, a Markov model was constructed such that the sum of rotavirus-associated hospitalizations and outpatient visits was set a constant value of 129 cases per 1,000 child-years. We calculated the direct medical cost, the indirect cost, and the quality-adjusted life year (QALY) loss in children aged less than 5 years. For the base case scenario, the incremental costeffectiveness ratio (ICER) per QALY gained was \9.8 million from the healthcare perspective, but it was \900,000 from the societal perspective, making the program of universal immunization against rotavirus highly cost-effective. Furthermore, the universal immunization program was found to be cost-effective from the societal perspective for any of the previously reported incidence rates of rotavirus-associated hospitalization. Thus, the introduction of the rotavirus vaccine into the childhood immunization schedule and its co-administration with other childhood vaccines will be a cost-effective public health intervention in Japan.